Biodesix Inc (BDSX)vsDanaher Corporation (DHR)
BDSX
Biodesix Inc
$17.35
-6.30%
HEALTHCARE · Cap: $161.55M
DHR
Danaher Corporation
$178.19
+0.58%
HEALTHCARE · Cap: $128.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 25685% more annual revenue ($24.78B vs $96.10M). DHR leads profitability with a 14.9% profit margin vs -33.3%. DHR earns a higher WallStSmart Score of 58/100 (C).
BDSX
Avoid31
out of 100
Grade: F
DHR
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.0%
Fair Value
$8.70
Current Price
$17.35
$8.65 premium
Margin of Safety
-54.3%
Fair Value
$114.84
Current Price
$178.19
$63.35 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.3% year-over-year
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Areas to Watch
Trading at 19.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -349.9% — below average capital efficiency
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 42.3% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bear Case : BDSX
The primary concerns for BDSX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 7.84 is elevated, increasing financial risk.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
BDSX profiles as a hypergrowth stock while DHR is a value play — different risk/reward profiles.
DHR carries more volatility with a beta of 0.83 — expect wider price swings.
BDSX is growing revenue faster at 42.3% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (58/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?